1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014

Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 24 pages

Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014’, provides an overview of the Biolab Sanus Farmaceutica Ltda.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biolab Sanus Farmaceutica Ltda.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biolab Sanus Farmaceutica Ltda. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biolab Sanus Farmaceutica Ltda.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Biolab Sanus Farmaceutica Ltda.’s pipeline products

Reasons to buy

- Evaluate Biolab Sanus Farmaceutica Ltda.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biolab Sanus Farmaceutica Ltda. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biolab Sanus Farmaceutica Ltda.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biolab Sanus Farmaceutica Ltda. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biolab Sanus Farmaceutica Ltda.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biolab Sanus Farmaceutica Ltda. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Biolab Sanus Farmaceutica Ltda. - Product Pipeline Review - 2014
Table of Contents
Biolab Sanus Farmaceutica Ltda. Snapshot 4
Biolab Sanus Farmaceutica Ltda. Overview 4
Key Information 4
Key Facts 4
Biolab Sanus Farmaceutica Ltda.- Research and Development Overview 5
Key Therapeutic Areas 5
Biolab Sanus Farmaceutica Ltda.- Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products- Monotherapy 8
Biolab Sanus Farmaceutica Ltda.- Pipeline Products Glance 9
Biolab Sanus Farmaceutica Ltda.- Late Stage Pipeline Products 9
Phase III Products/Combination Treatment Modalities 9
Biolab Sanus Farmaceutica Ltda.- Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Biolab Sanus Farmaceutica Ltda.- Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Biolab Sanus Farmaceutica Ltda.- Drug Profiles 12
BL-123 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
BL-125 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
PB-5109 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
BL-122 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
BL-214 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
BL-249 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Biolab Sanus Farmaceutica Ltda.- Pipeline Analysis 18
Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Target 18
Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Route of Administration 19
Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Molecule Type 20
Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Mechanism of Action 21
Biolab Sanus Farmaceutica Ltda.- Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables

Biolab Sanus Farmaceutica Ltda., Key Information 4
Biolab Sanus Farmaceutica Ltda., Key Facts 4
Biolab Sanus Farmaceutica Ltda.- Pipeline by Indication, 2014 6
Biolab Sanus Farmaceutica Ltda.- Pipeline by Stage of Development, 2014 7
Biolab Sanus Farmaceutica Ltda.- Monotherapy Products in Pipeline, 2014 8
Biolab Sanus Farmaceutica Ltda.- Phase III, 2014 9
Biolab Sanus Farmaceutica Ltda.- Phase I, 2014 10
Biolab Sanus Farmaceutica Ltda.- Preclinical, 2014 11
Biolab Sanus Farmaceutica Ltda. -Pipeline by Target, 2014 18
Biolab Sanus Farmaceutica Ltda.- Pipeline by Route of Administration, 2014 19
Biolab Sanus Farmaceutica Ltda.- Pipeline by Molecule Type, 2014 20
Biolab Sanus Farmaceutica Ltda.- Pipeline Products by Mechanism of Action, 2014 21
Biolab Sanus Farmaceutica Ltda., Other Locations 22

List of Figures

Biolab Sanus Farmaceutica Ltda. - Pipeline by Top 10 Indication, 2014 6
Biolab Sanus Farmaceutica Ltda. - Pipeline by Stage of Development, 2014 7
Biolab Sanus Farmaceutica Ltda. - Monotherapy Products in Pipeline, 2014 8
Biolab Sanus Farmaceutica Ltda. - Pipeline by Top 10 Molecule Type, 2014 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.